Ultrasound‐guided injection of the iliopsoas muscle with botulinum toxin in camptocormia
Identifieur interne : 003004 ( Istex/Corpus ); précédent : 003003; suivant : 003005Ultrasound‐guided injection of the iliopsoas muscle with botulinum toxin in camptocormia
Auteurs : Rainer Von Coelln ; Armin Raible ; Thomas Gasser ; Friedrich AsmusSource :
- Movement Disorders [ 0885-3185 ] ; 2008-04-30.
English descriptors
Abstract
Camptocormia is characterized by an abnormal posture of the trunk with pronounced flexion of the thoraco‐lumbar spine during standing and walking, which abates in a supine position. Treatment options for camptocormia are limited and mostly futile. Here, we report on the ultrasound‐guided ventral injection of botulinum toxin A (BTX) into deep portions of the iliopsoas muscle in four parkinsonian patients with camptocormia as chief complaint. Using this novel and safe application technique, all patients received 500–1,500 MU of BTX per side in 4–6 month intervals. Treatment was generally well tolerated. At the highest dose, all patients complained of mild weakness of hip flexion. Standardized physical exam at follow‐up visits, as well as self‐assessment of patients, failed to show a relevant and lasting improvement of posture. In conclusion, injection of BTX into the iliopsoas does not appear to be a promising approach for the treatment of parkinsonism‐associated camptocormia. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.21967
Links to Exploration step
ISTEX:F7DC47417E5C6A6F620009971F8A38AC343F2D16Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ultrasound‐guided injection of the iliopsoas muscle with botulinum toxin in camptocormia</title><author><name sortKey="Von Coelln, Rainer" sort="Von Coelln, Rainer" uniqKey="Von Coelln R" first="Rainer" last="Von Coelln">Rainer Von Coelln</name><affiliation><mods:affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Raible, Armin" sort="Raible, Armin" uniqKey="Raible A" first="Armin" last="Raible">Armin Raible</name><affiliation><mods:affiliation>Department of Internal Medicine I, University of Tuebingen,Tuebingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name><affiliation><mods:affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Asmus, Friedrich" sort="Asmus, Friedrich" uniqKey="Asmus F" first="Friedrich" last="Asmus">Friedrich Asmus</name><affiliation><mods:affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F7DC47417E5C6A6F620009971F8A38AC343F2D16</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.21967</idno><idno type="url">https://api.istex.fr/document/F7DC47417E5C6A6F620009971F8A38AC343F2D16/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003004</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ultrasound‐guided injection of the iliopsoas muscle with botulinum toxin in camptocormia</title><author><name sortKey="Von Coelln, Rainer" sort="Von Coelln, Rainer" uniqKey="Von Coelln R" first="Rainer" last="Von Coelln">Rainer Von Coelln</name><affiliation><mods:affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Raible, Armin" sort="Raible, Armin" uniqKey="Raible A" first="Armin" last="Raible">Armin Raible</name><affiliation><mods:affiliation>Department of Internal Medicine I, University of Tuebingen,Tuebingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name><affiliation><mods:affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Asmus, Friedrich" sort="Asmus, Friedrich" uniqKey="Asmus F" first="Friedrich" last="Asmus">Friedrich Asmus</name><affiliation><mods:affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-04-30">2008-04-30</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="889">889</biblScope><biblScope unit="page" to="892">892</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F7DC47417E5C6A6F620009971F8A38AC343F2D16</idno><idno type="DOI">10.1002/mds.21967</idno><idno type="ArticleID">MDS21967</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>botulinum toxin A</term><term>camptocormia</term><term>iliopsoas</term><term>psoas major</term><term>ultrasound‐guidance</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Camptocormia is characterized by an abnormal posture of the trunk with pronounced flexion of the thoraco‐lumbar spine during standing and walking, which abates in a supine position. Treatment options for camptocormia are limited and mostly futile. Here, we report on the ultrasound‐guided ventral injection of botulinum toxin A (BTX) into deep portions of the iliopsoas muscle in four parkinsonian patients with camptocormia as chief complaint. Using this novel and safe application technique, all patients received 500–1,500 MU of BTX per side in 4–6 month intervals. Treatment was generally well tolerated. At the highest dose, all patients complained of mild weakness of hip flexion. Standardized physical exam at follow‐up visits, as well as self‐assessment of patients, failed to show a relevant and lasting improvement of posture. In conclusion, injection of BTX into the iliopsoas does not appear to be a promising approach for the treatment of parkinsonism‐associated camptocormia. © 2008 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Rainer von Coelln MD</name><affiliations><json:string>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</json:string></affiliations></json:item><json:item><name>Armin Raible MD</name><affiliations><json:string>Department of Internal Medicine I, University of Tuebingen,Tuebingen, Germany</json:string></affiliations></json:item><json:item><name>Thomas Gasser MD</name><affiliations><json:string>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</json:string></affiliations></json:item><json:item><name>Friedrich Asmus MD</name><affiliations><json:string>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>iliopsoas</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>psoas major</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>camptocormia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>botulinum toxin A</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ultrasound‐guidance</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Camptocormia is characterized by an abnormal posture of the trunk with pronounced flexion of the thoraco‐lumbar spine during standing and walking, which abates in a supine position. Treatment options for camptocormia are limited and mostly futile. Here, we report on the ultrasound‐guided ventral injection of botulinum toxin A (BTX) into deep portions of the iliopsoas muscle in four parkinsonian patients with camptocormia as chief complaint. Using this novel and safe application technique, all patients received 500–1,500 MU of BTX per side in 4–6 month intervals. Treatment was generally well tolerated. At the highest dose, all patients complained of mild weakness of hip flexion. Standardized physical exam at follow‐up visits, as well as self‐assessment of patients, failed to show a relevant and lasting improvement of posture. In conclusion, injection of BTX into the iliopsoas does not appear to be a promising approach for the treatment of parkinsonism‐associated camptocormia. © 2008 Movement Disorder Society</abstract><qualityIndicators><score>3.956</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1022</abstractCharCount><pdfWordCount>2132</pdfWordCount><pdfCharCount>13905</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>152</abstractWordCount></qualityIndicators><title>Ultrasound‐guided injection of the iliopsoas muscle with botulinum toxin in camptocormia</title><genre><json:string>Serial article</json:string></genre><host><volume>23</volume><pages><total>4</total><last>892</last><first>889</first></pages><issn><json:string>0885-3185</json:string></issn><issue>6</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/mds.21967</json:string></doi><id>F7DC47417E5C6A6F620009971F8A38AC343F2D16</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/F7DC47417E5C6A6F620009971F8A38AC343F2D16/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/F7DC47417E5C6A6F620009971F8A38AC343F2D16/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F7DC47417E5C6A6F620009971F8A38AC343F2D16/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Ultrasound‐guided injection of the iliopsoas muscle with botulinum toxin in camptocormia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2008</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Ultrasound‐guided injection of the iliopsoas muscle with botulinum toxin in camptocormia</title><author><persName><forename type="first">Rainer</forename><surname>von Coelln</surname><roleName type="degree">MD</roleName></persName><affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</affiliation></author><author><persName><forename type="first">Armin</forename><surname>Raible</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Internal Medicine I, University of Tuebingen,Tuebingen, Germany</affiliation></author><author><persName><forename type="first">Thomas</forename><surname>Gasser</surname><roleName type="degree">MD</roleName></persName><affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</affiliation></author><author><persName><forename type="first">Friedrich</forename><surname>Asmus</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Dystonia and Botulinumtoxin Clinic, Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, Otfried‐Muller Str. 27, 4th floor, D‐72076 Tuebingen, Germany</p></note><affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-04-30"></date><biblScope unit="vol">23</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="889">889</biblScope><biblScope unit="page" to="892">892</biblScope></imprint></monogr><idno type="istex">F7DC47417E5C6A6F620009971F8A38AC343F2D16</idno><idno type="DOI">10.1002/mds.21967</idno><idno type="ArticleID">MDS21967</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Camptocormia is characterized by an abnormal posture of the trunk with pronounced flexion of the thoraco‐lumbar spine during standing and walking, which abates in a supine position. Treatment options for camptocormia are limited and mostly futile. Here, we report on the ultrasound‐guided ventral injection of botulinum toxin A (BTX) into deep portions of the iliopsoas muscle in four parkinsonian patients with camptocormia as chief complaint. Using this novel and safe application technique, all patients received 500–1,500 MU of BTX per side in 4–6 month intervals. Treatment was generally well tolerated. At the highest dose, all patients complained of mild weakness of hip flexion. Standardized physical exam at follow‐up visits, as well as self‐assessment of patients, failed to show a relevant and lasting improvement of posture. In conclusion, injection of BTX into the iliopsoas does not appear to be a promising approach for the treatment of parkinsonism‐associated camptocormia. © 2008 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>iliopsoas</term></item><item><term>psoas major</term></item><item><term>camptocormia</term></item><item><term>botulinum toxin A</term></item><item><term>ultrasound‐guidance</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-11-05">Received</change><change when="2008-01-13">Registration</change><change when="2008-04-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/F7DC47417E5C6A6F620009971F8A38AC343F2D16/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/mds.v23:6</doi><numberingGroup><numbering type="journalVolume" number="23">23</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2008-04-30">30 April 2008</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="190" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21967</doi><idGroup><id type="unit" value="MDS21967"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-11-05"></event><event type="manuscriptRevised" date="2008-01-09"></event><event type="manuscriptAccepted" date="2008-01-13"></event><event type="firstOnline" date="2008-02-28"></event><event type="publishedOnlineFinalForm" date="2008-04-24"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2008-02-28"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">889</numbering><numbering type="pageLast">892</numbering></numberingGroup><correspondenceTo>Dystonia and Botulinumtoxin Clinic, Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, Otfried‐Muller Str. 27, 4th floor, D‐72076 Tuebingen, Germany</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21967.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="15"></count><count type="wordTotal" number="2567"></count></countGroup><titleGroup><title type="main" xml:lang="en">Ultrasound‐guided injection of the iliopsoas muscle with botulinum toxin in camptocormia</title><title type="short" xml:lang="en">Botulinum Toxin in Camptocormia</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Rainer</givenNames><familyName>von Coelln</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Armin</givenNames><familyName>Raible</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Thomas</givenNames><familyName>Gasser</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Friedrich</givenNames><familyName>Asmus</familyName><degrees>MD</degrees></personName><contactDetails><email normalForm="friedrich.asmus@uni-tuebingen.de">friedrich.asmus@uni‐tuebingen.de</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="DE" type="organization"><unparsedAffiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="DE" type="organization"><unparsedAffiliation>Department of Internal Medicine I, University of Tuebingen,Tuebingen, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">iliopsoas</keyword><keyword xml:id="kwd2">psoas major</keyword><keyword xml:id="kwd3">camptocormia</keyword><keyword xml:id="kwd4">botulinum toxin A</keyword><keyword xml:id="kwd5">ultrasound‐guidance</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Camptocormia is characterized by an abnormal posture of the trunk with pronounced flexion of the thoraco‐lumbar spine during standing and walking, which abates in a supine position. Treatment options for camptocormia are limited and mostly futile. Here, we report on the ultrasound‐guided ventral injection of botulinum toxin A (BTX) into deep portions of the iliopsoas muscle in four parkinsonian patients with camptocormia as chief complaint. Using this novel and safe application technique, all patients received 500–1,500 MU of BTX per side in 4–6 month intervals. Treatment was generally well tolerated. At the highest dose, all patients complained of mild weakness of hip flexion. Standardized physical exam at follow‐up visits, as well as self‐assessment of patients, failed to show a relevant and lasting improvement of posture. In conclusion, injection of BTX into the iliopsoas does not appear to be a promising approach for the treatment of parkinsonism‐associated camptocormia. © 2008 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Ultrasound‐guided injection of the iliopsoas muscle with botulinum toxin in camptocormia</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Botulinum Toxin in Camptocormia</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Ultrasound‐guided injection of the iliopsoas muscle with botulinum toxin in camptocormia</title></titleInfo><name type="personal"><namePart type="given">Rainer</namePart><namePart type="family">von Coelln</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Armin</namePart><namePart type="family">Raible</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Internal Medicine I, University of Tuebingen,Tuebingen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thomas</namePart><namePart type="family">Gasser</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Friedrich</namePart><namePart type="family">Asmus</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany</affiliation><description>Correspondence: Dystonia and Botulinumtoxin Clinic, Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, Otfried‐Muller Str. 27, 4th floor, D‐72076 Tuebingen, Germany</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008-04-30</dateIssued><dateCaptured encoding="w3cdtf">2007-11-05</dateCaptured><dateValid encoding="w3cdtf">2008-01-13</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">15</extent><extent unit="words">2567</extent></physicalDescription><abstract lang="en">Camptocormia is characterized by an abnormal posture of the trunk with pronounced flexion of the thoraco‐lumbar spine during standing and walking, which abates in a supine position. Treatment options for camptocormia are limited and mostly futile. Here, we report on the ultrasound‐guided ventral injection of botulinum toxin A (BTX) into deep portions of the iliopsoas muscle in four parkinsonian patients with camptocormia as chief complaint. Using this novel and safe application technique, all patients received 500–1,500 MU of BTX per side in 4–6 month intervals. Treatment was generally well tolerated. At the highest dose, all patients complained of mild weakness of hip flexion. Standardized physical exam at follow‐up visits, as well as self‐assessment of patients, failed to show a relevant and lasting improvement of posture. In conclusion, injection of BTX into the iliopsoas does not appear to be a promising approach for the treatment of parkinsonism‐associated camptocormia. © 2008 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>iliopsoas</topic><topic>psoas major</topic><topic>camptocormia</topic><topic>botulinum toxin A</topic><topic>ultrasound‐guidance</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>889</start><end>892</end><total>4</total></extent></part></relatedItem><identifier type="istex">F7DC47417E5C6A6F620009971F8A38AC343F2D16</identifier><identifier type="DOI">10.1002/mds.21967</identifier><identifier type="ArticleID">MDS21967</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003004 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003004 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F7DC47417E5C6A6F620009971F8A38AC343F2D16
|texte= Ultrasound‐guided injection of the iliopsoas muscle with botulinum toxin in camptocormia
}}
| This area was generated with Dilib version V0.6.23. |  |